| Field | Specification |
|---|---|
| Target | |
| Alternative names | Disintegrin and metalloproteinase domain-containing protein 9; ADAM 9; Cellular disintegrin-related protein; Meltrin-gamma; Metalloprotease/disintegrin/cysteine-rich protein 9; Myeloma cell metalloproteinase; ADAM9; KIAA0021; MCMP; MDC9; MLTNG |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | E.coli-derived human ADAM9 recombinant protein (Position: R212-D247). |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody recognizes disintegrin and metalloproteinase domain-containing protein 9 (gene ADAM9) in human samples and is validated for Western blot, IHC, ICC/IF and ELISA. The predicted molecular weight is 90.6 kDa, and the supplier reports an observed band at about 75 kDa.
ADAM9 is a membrane metalloprotease that cleaves proteins such as VE-cadherin, VEGFR2 and CD40 and interacts with integrins. It affects cell adhesion, migration and angiogenesis, and it is studied in tumor progression and eye disease.
| Target | Disintegrin and metalloproteinase domain-containing protein 9 (gene ADAM9; UniProt Q13443, human) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | Human |
| Form | Lyophilized |
| Formulation | Per vial: 4 mg trehalose; 0.9 mg NaCl; 0.2 mg Na2HPO4 |
| Calculated MW | 90.6 kDa |
| Observed MW | 75 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.25–0.5 µg/mL (Human) |
|---|---|
| IHC (paraffin sections) | 2–5 µg/mL (Human) |
| Immunocytochemistry / Immunofluorescence | 5 µg/mL (Human) |
| ELISA | 0.1–0.5 µg/mL |
Samples with a confirmed band (WB): human U-87MG cells, human A431 cells.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 30 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:5000, ECL detection.
Samples with confirmed staining (IHC): human bladder adenosquamous carcinoma tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in EDTA buffer (pH 8.0).
Samples with confirmed staining (ICC/IF): U2OS cells.
Immunogen
Recombinant human ADAM9 fragment (Arg212–Asp247), expressed in E. coli.
Reactivity Notes
The supplier lists reactivity with human. Tissue expression noted by UniProt (human): Widely expressed. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
Guofu Lin et al. (2026) Multi-omics profiling identifies ADAM9 as a key efferocytosis driver in lung adenocarcinoma. Frontiers in Immunology. 10.3389/fimmu.2026.1772167
Ting Guo et al. (2019) Aberrant expression of ADAM9 in ovarian cancer and its clinical significance. Journal of Clinical Laboratory Analysis. 10.1002/jcla.23136
